Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.

Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.

While not disclosing a specific launch timeframe, with de novo clearance in hand, J&J initially plans to launch Ottava with “select customers”.

Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.

Health technology brand Hilo, developed by Aktiia, has launched its Hilo Core blood pressure monitoring system in the US.

Cardinal Health’s acquisitions of Strive Medical and Adapt Health’s diabetes unit are collectively intended to support its at-home care business’s growth strategy.

British Business Bank has previously co-invested in EQT's fund portfolio companies Phagenesis and Cyted Health.

GE HealthCare's tool is intended to streamline imaging workflow collaboration between different specialist teams in areas such as oncology.

Fresenius Medical Care has introduced TherapyWise, a cloud-based analytics platform aimed at supporting hospital and critical care teams overseeing KRT in the US.

Following TYBR’s B3 GEL’s US launch in January 2026, the company primarily intends to use the funds to expand market access to the hydrogel.

Advancements in artificial intelligence, precision medicine, and digital health pave the way for innovation that enhances patient care, improves efficiency, and addresses evolving regulatory and ...